 Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gileads Cancer Program Notches Another Win, But Its Arcus Stock That Surges appeared first on Investors Business Daily. 